

Gordon C Jayson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6470672/publications.pdf>

Version: 2024-02-01

213
papers

18,961
citations

23879

60
h-index

14012

133
g-index

215
all docs

215
docs citations

215
times ranked

22818
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status. <i>Sexual Medicine</i> , 2022, 10, 100465.	0.9	0
2	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. <i>BMC Medicine</i> , 2022, 20, 59.	2.3	3
3	A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. <i>British Journal of Cancer</i> , 2022, 127, 92-101.	2.9	4
4	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	5.1	34
5	Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. <i>ESMO Open</i> , 2021, 6, 100043.	2.0	16
6	Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. <i>BMC Cancer</i> , 2021, 21, 354.	1.1	1
7	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	3
8	Psychosexual morbidity in women with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1983-1989.	1.2	12
9	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , 2020, 22, 64.	1.8	30
10	Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition. <i>Journal of Human Nutrition and Dietetics</i> , 2020, 33, 550-556.	1.3	10
11	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. <i>Nature Communications</i> , 2020, 11, 822.	5.8	62
12	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	0.6	14
13	Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision. <i>Nutrients</i> , 2020, 12, 166.	1.7	13
14	FP395CANCER HISTORY IS ASSOCIATED WITH MORTALITY BUT NOT WITH RENAL PROGRESSION IN NON-DIALYSIS CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
15	Imaging Tumor Angiogenesis. , 2019, , 277-290.		1
16	Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. <i>Journal of Medical Genetics</i> , 2019, 56, 301-307.	1.5	21
17	Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. <i>European Journal of Cancer</i> , 2019, 117, 48-59.	1.3	5
18	Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. <i>ESMO Open</i> , 2019, 4, e000463.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 341-345.	1.2	1
20	Dynamics of circulating vascular endothelial growth factor predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1781-1789.	1.1	3
21	Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers. <i>BMC Palliative Care</i> , 2019, 18, 120.	0.8	33
22	An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 448-452.	1.2	1
23	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 647-658.	1.1	58
24	Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 173-179.	0.6	19
25	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687.	5.1	187
26	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018, 9, 4672.	5.8	47
27	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
28	Imaging Tumor Angiogenesis. , 2017, , 1-14.		0
29	Herceptin in the Adjuvant Treatment of Breast Cancer. , 2017, , 257-259.		0
30	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	2.9	23
31	An Updated Synthesis of the Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrogen Sulfate. <i>Journal of Organic Chemistry</i> , 2016, 81, 3443-3446.	1.7	56
32	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1066-1074.	6.3	216
33	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2016, 28, 760-765.	0.6	7
34	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet</i> , The, 2016, 388, 518-529.	6.3	663
35	Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. <i>PLoS ONE</i> , 2016, 11, e0159739.	1.1	8
36	Mixed-effects modeling of clinical DCE-MRI data: Application to colorectal liver metastases treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 132-141.	1.9	9

#	ARTICLE	IF	CITATIONS
37	Modular Synthesis of Heparin-Related Tetra-, Hexa- and Octasaccharides with Differential O-6 Protections: Programming for Regiodefined 6-O-Modifications. <i>Molecules</i> , 2015, 20, 6167-6180.	1.7	12
38	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2015, 386, 249-257.	6.3	1,042
39	Amyl nitrite-mediated conversion of aromatic and heteroaromatic primary amides to carboxylic acids. <i>Tetrahedron Letters</i> , 2015, 56, 5153-5156.	0.7	7
40	PARP inhibitors in BRCA mutation-associated ovarian cancer. <i>Lancet Oncology, The</i> , 2015, 16, 10-12.	5.1	18
41	Synthesis of α -Iduronic Acid Derivatives via [3.2.1] and [2.2.2] α -Iduronic Lactones from Bulk Glucose-Derived Cyanohydrin Hydrolysis: A Reversible Conformationally Switched Superdisarmed/Rearmed Lactone Route to Heparin Disaccharides. <i>Journal of Organic Chemistry</i> , 2015, 80, 3777-3789.	1.7	17
42	Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology. <i>Chemical Communications</i> , 2015, 51, 13846-13849.	2.2	35
43	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015, 16, 928-936.	5.1	661
44	Molecular phenotyping of a UK population: defining the human serum metabolome. <i>Metabolomics</i> , 2015, 11, 9-26.	1.4	202
45	A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 11208-11219.	1.5	10
46	Making the longest sugars: a chemical synthesis of heparin-related [4] _n oligosaccharides from 16-mer to 40-mer. <i>Chemical Science</i> , 2015, 6, 6158-6164.	3.7	77
47	Segregation of late outgrowth endothelial cells into functional endothelial CD34 ⁺ and progenitor-like CD34 ⁺ cell populations. <i>Angiogenesis</i> , 2015, 18, 47-68.	3.7	25
48	Clinical Trial Participation and Outcomes in Ovarian Cancer: a Case Control Study. <i>Annals of Oncology</i> , 2014, 25, iv317.	0.6	1
49	Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by Heparin-binding Epidermal Growth Factor (EGF)-like Growth Factor/EGF Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2014, 289, 10488-10501.	1.6	48
50	No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. <i>British Journal of Cancer</i> , 2014, 111, 589-597.	2.9	14
51	The development of anti-angiogenic heparan sulfate oligosaccharides. <i>Biochemical Society Transactions</i> , 2014, 42, 1596-1600.	1.6	6
52	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4549-4558.	3.2	63
53	Biomarkers and Response to Bevacizumab [®] Response. <i>Clinical Cancer Research</i> , 2014, 20, 1058-1058.	3.2	1
54	Accessing cancer services in North West England: the Chinese population. <i>European Journal of Cancer Care</i> , 2014, 23, 570-581.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 430-434.	1.1	24
56	Synthesis of a heparin-related GlcNAc-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy. <i>Carbohydrate Research</i> , 2014, 400, 44-53.	1.1	17
57	Thrombosis in ovarian cancer: a case control study. <i>British Journal of Cancer</i> , 2014, 110, 1118-1124.	2.9	49
58	Ovarian cancer. <i>Lancet</i> , The, 2014, 384, 1376-1388.	6.3	1,491
59	Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: Application to dynamic contrast-enhanced MRI biomarkers. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1299-1311.	1.9	6
60	Small-Molecule-Induced Clustering of Heparan Sulfate Promotes Cell Adhesion. <i>Journal of the American Chemical Society</i> , 2013, 135, 11032-11039.	6.6	25
61	Efficient chemical synthesis of heparin-like octa-, deca- and dodecasaccharides and inhibition of FGF2- and VEGF165-mediated endothelial cell functions. <i>Chemical Science</i> , 2013, 4, 3218.	3.7	36
62	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1343-1352.	1.1	33
63	First Gram-Scale Synthesis of a Heparin-Related Dodecasaccharide. <i>Organic Letters</i> , 2013, 15, 88-91.	2.4	46
64	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , 2013, 108, 250-258.	2.9	64
65	Angiogenesis as a target for the treatment of ovarian cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 558-565.	1.1	25
66	Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. <i>Clinical Cancer Research</i> , 2013, 19, 5227-5239.	3.2	63
67	Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies. <i>Nature Communications</i> , 2013, 4, 2016.	5.8	50
68	Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 5500-5500.	0.8	55
69	Endothelial Heparan Sulfate 6-O-Sulfation Levels Regulate Angiogenic Responses of Endothelial Cells to Fibroblast Growth Factor 2 and Vascular Endothelial Growth Factor. <i>Journal of Biological Chemistry</i> , 2012, 287, 36132-36146.	1.6	63
70	Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?. <i>Clinical Cancer Research</i> , 2012, 18, 6588-6598.	3.2	50
71	Dynamic contrast-enhanced MRI in clinical trials of antivasular therapies. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 167-177.	12.5	318
72	Synthesis and Scalable Conversion of Iduronamides to Heparin-Related Di- and Tetrasaccharides. <i>Journal of Organic Chemistry</i> , 2012, 77, 7823-7843.	1.7	42

#	ARTICLE	IF	CITATIONS
73	Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 283-293.	1.5	26
74	Antiangiogenic therapy—evolving view based on clinical trial results. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 297-303.	12.5	137
75	DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 196-203.	1.9	25
76	Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , 2011, 22, 2036-2041.	0.6	140
77	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	13.9	1,843
78	A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer. <i>Journal of Psychosomatic Research</i> , 2011, 70, 422-431.	1.2	38
79	VEGF inhibitors and advanced ovarian cancer. <i>Lancet Oncology</i> , The, 2011, 12, 1082-1083.	5.1	2
80	Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 58-65.	1.2	55
81	A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 631-641.	1.1	22
82	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3798-3804.	0.8	203
83	A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , 2011, 22, 2411-2416.	0.6	24
84	DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. <i>British Journal of Cancer</i> , 2011, 105, 139-145.	2.9	123
85	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , 2011, 22, 1413-1419.	0.6	69
86	“Risky” research and participants' interests: the ethics of phase 2C clinical trials. <i>Clinical Ethics</i> , 2011, 6, 91-96.	0.5	9
87	Novel Anti-angiogenic Therapies in Ovarian Cancer. , 2011, , 51-72.		0
88	Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 495-504.	1.5	91
89	A Longitudinal Investigation of Psychological Disorders in Patients Prior and Subsequent to a Diagnosis of Ovarian Cancer. <i>Journal of Clinical Psychology in Medical Settings</i> , 2010, 17, 167-173.	0.8	11
90	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. <i>British Journal of Cancer</i> , 2010, 102, 8-18.	2.9	217

#	ARTICLE	IF	CITATIONS
91	Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. British Journal of Cancer, 2010, 102, 1524-1532.	2.9	13
92	Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 2010, 16, 4899-4905.	3.2	46
93	Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Annals of Oncology, 2010, 21, 1982-1989.	0.6	27
94	389 A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW. European Journal of Cancer, Supplement, 2010, 8, 123-124.	2.2	1
95	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, The, 2010, 376, 1155-1163.	6.3	497
96	The ethical and scientific case for phase 2C clinical trials. Lancet Oncology, The, 2010, 11, 410-411.	5.1	4
97	Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology, 2010, 7, 69-82.	1.9	27
98	Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2010, 28, e13580-e13580.	0.8	5
99	Synthetic Heparan Sulfate Oligosaccharides Inhibit Endothelial Cell Functions Essential for Angiogenesis. PLoS ONE, 2010, 5, e11644.	1.1	48
100	Cross-Visit Tumor Sub-segmentation and Registration with Outlier Rejection for Dynamic Contrast-Enhanced MRI Time Series Data. Lecture Notes in Computer Science, 2010, 13, 121-128.	1.0	4
101	Selective inhibition of proliferating endothelial cells: A phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors.. Journal of Clinical Oncology, 2010, 28, TPS167-TPS167.	0.8	0
102	Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. Clinical Cancer Research, 2009, 15, 6674-6682.	3.2	142
103	“Fit-for-purpose”™ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Journal of Immunological Methods, 2009, 342, 106-114.	0.6	33
104	Comparison of normal tissue R_2 and R_2^* modulation by oxygen and carbogen. Magnetic Resonance in Medicine, 2009, 61, 75-83.	1.9	77
105	Antiangiogenic drugs in ovarian cancer. British Journal of Cancer, 2009, 100, 1-7.	2.9	84
106	Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in MRI: A Potential Novel Biomarker of Oxygenation Changes in Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1209-1215.	0.4	107
107	Scalable Synthesis of I-Iduronic Acid Derivatives via Stereocontrolled Cyanohydrin Reaction for Synthesis of Heparin-Related Disaccharides. Organic Letters, 2009, 11, 4528-4531.	2.4	41
108	New therapeutic agents in ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2009, 21, 44-53.	0.9	17

#	ARTICLE	IF	CITATIONS
109	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 579-585.	1.1	17
110	Synthesis of [¹⁸ F]fluoroacetaldehyde. Application to [¹⁸ F]fluoroethylation of benzylamine under reductive alkylation conditions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 262-267.	0.5	11
111	A longitudinal investigation of psychological morbidity in patients with ovarian cancer. <i>British Journal of Cancer</i> , 2008, 99, 1794-1801.	2.9	49
112	Quantitative multiplexed quantum dot immunohistochemistry. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 181-186.	1.0	57
113	Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. <i>Lancet Oncology</i> , The, 2008, 9, 766-776.	5.1	150
114	Angiogenesis as a therapeutic target in cancer. <i>Clinical Medicine</i> , 2008, 8, 455-458.	0.8	14
115	Oligosaccharides as anti-angiogenic agents. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 351-362.	1.4	18
116	Better Life Expectancy in Women with <i>BRCA2</i> Compared with <i>BRCA1</i> Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1535-1542.	1.1	15
117	Development of antiangiogenic agents for ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 21-32.	1.1	4
118	The Role of Imaging in the Clinical Development of Antiangiogenic Agents. , 2008, , 525-536.		4
119	Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases. <i>Journal of Clinical Oncology</i> , 2008, 26, 3506-3506.	0.8	4
120	The effect of food on the single dose pharmacokinetics of cediranib. <i>Journal of Clinical Oncology</i> , 2008, 26, 14533-14533.	0.8	0
121	Pharmacodynamic assessment of the anti-angiogenic and anti-vascular properties of bevacizumab by magnetic resonance imaging in metastatic colorectal carcinoma (CRC). <i>Journal of Clinical Oncology</i> , 2008, 26, 3546-3546.	0.8	0
122	Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis. , 2008, , 511-528.		0
123	Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 6130-6135.	3.2	23
124	Heparan sulphate synthetic and editing enzymes in ovarian cancer. <i>British Journal of Cancer</i> , 2007, 96, 1544-1548.	2.9	50
125	Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>Clinical Cancer Research</i> , 2007, 13, 3449-3459.	3.2	293
126	Phase I Evaluation of a Fully Human Anti- $\alpha_5\beta_1$ Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2128-2135.	3.2	136

#	ARTICLE	IF	CITATIONS
127	Phase I Evaluation of CDP791, a PEGylated Di-Fab ² Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2. <i>Clinical Cancer Research</i> , 2007, 13, 7113-7118.	3.2	69
128	Antiangiogenic therapy for ovarian cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 497-505.	1.1	12
129	DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. <i>British Journal of Cancer</i> , 2007, 96, 189-195.	2.9	467
130	Alpha-v Integrins as Therapeutic Targets in Oncology. <i>Cancer Investigation</i> , 2007, 25, 632-646.	0.6	94
131	Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 490-496.	1.9	75
132	Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 1010-1019.	1.9	71
133	The Neoadjuvant Approach in the Treatment of Patients with Advanced Epithelial Ovarian Carcinoma. <i>Clinical Oncology</i> , 2007, 19, 125-128.	0.6	2
134	Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. <i>Colorectal Disease</i> , 2007, 9, 793-800.	0.7	53
135	Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. <i>Cancer Science</i> , 2007, 98, 844-849.	1.7	19
136	Comparison of the Performance of Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Using Different Models of Contrast Enhancement. <i>Academic Radiology</i> , 2006, 13, 1112-1123.	1.3	43
137	A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 867-876.	1.5	78
138	Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy. <i>European Journal of Cancer</i> , 2006, 42, 112-117.	1.3	66
139	The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. <i>European Journal of Surgical Oncology</i> , 2006, 32, 588-591.	0.5	20
140	Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 18-24.	1.2	8
141	How participants in cancer trials are chosen: ethics and conflicting interests. <i>Nature Reviews Cancer</i> , 2006, 6, 330-336.	12.8	18
142	SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel+irinotecan as first-line therapy for ovarian cancer. <i>British Journal of Cancer</i> , 2006, 94, 55-61.	2.9	10
143	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 41-44.	1.2	9
144	Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 2006, 56, 993-1000.	1.9	574

#	ARTICLE	IF	CITATIONS
145	The Best Guess Approach to Phase I Trial Design. <i>Journal of Clinical Oncology</i> , 2006, 24, 206-208.	0.8	16
146	The Morphogenic Properties of Oligomeric Endostatin Are Dependent on Cell Surface Heparan Sulfate. <i>Journal of Biological Chemistry</i> , 2006, 281, 14813-14822.	1.6	7
147	Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. <i>British Journal of Cancer</i> , 2006, 95, 42-48.	2.9	60
148	Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 18-24.	1.2	3
149	Pre-operative Plasma Levels of Vascular Endothelial Growth Factor A, C and D in Patients with Colorectal Cancer. <i>Clinical Oncology</i> , 2005, 17, 367-371.	0.6	11
150	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. <i>Journal of Clinical Oncology</i> , 2005, 23, 973-981.	0.8	167
151	The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. <i>British Journal of Cancer</i> , 2005, 92, 1599-1610.	2.9	487
152	Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2005, 93, 647-651.	2.9	47
153	Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma. <i>Scientific World Journal</i> , The, 2005, 5, 230-233.	0.8	0
154	Heparin Octasaccharides Inhibit Angiogenesis In vivo. <i>Clinical Cancer Research</i> , 2005, 11, 8172-8179.	3.2	61
155	Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone. <i>Clinical Cancer Research</i> , 2005, 11, 2695-2701.	3.2	22
156	Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1859-1866.	0.8	66
157	Molecular Imaging of Antiangiogenic Agents. <i>Oncologist</i> , 2005, 10, 92-103.	1.9	134
158	Targeted antitumour therapy - future perspectives. <i>British Journal of Cancer</i> , 2005, 92, S28-S31.	2.9	14
159	The clinical potential of antiangiogenic fragments of extracellular matrix proteins. <i>British Journal of Cancer</i> , 2005, 93, 967-972.	2.9	43
160	Regulation of Fibroblast Growth Factor-2 Activity by Human Ovarian Cancer Tumor Endothelium. <i>Clinical Cancer Research</i> , 2005, 11, 4282-4288.	3.2	29
161	Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Time Series. <i>Lecture Notes in Computer Science</i> , 2005, 8, 91-98.	1.0	11
162	Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. <i>Drug Resistance Updates</i> , 2005, 8, 75-83.	6.5	113

#	ARTICLE	IF	CITATIONS
163	Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. <i>European Journal of Cancer</i> , 2005, 41, 555-563.	1.3	54
164	Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development. , 2005, , 281-297.		7
165	Resistance to Anti-VEGF Agents. <i>Current Pharmaceutical Design</i> , 2004, 10, 51-64.	0.9	20
166	Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5178-5186.	3.2	135
167	Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1682-1691.	3.0	562
168	Hypoxia Increases Heparanase-Dependent Tumor Cell Invasion, Which Can Be Inhibited by Antiheparanase Antibodies. <i>Cancer Research</i> , 2004, 64, 3928-3933.	0.4	59
169	Doctor, Does This Mean I'm Going to Starve to Death?. <i>Journal of Clinical Oncology</i> , 2004, 22, 199-201.	0.8	30
170	A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 95, 114-119.	0.6	10
171	Quantitative Angiogenesis Assays in vivo – A Review. <i>Angiogenesis</i> , 2004, 7, 1-16.	3.7	83
172	Social support, anxiety and depression after chemotherapy for ovarian cancer: A prospective study. <i>British Journal of Health Psychology</i> , 2004, 9, 569-581.	1.9	141
173	Vascular Endothelial Growth Factor Antagonists as Anticancer Agents. <i>American Journal of Cancer</i> , 2004, 3, 229-245.	0.4	0
174	Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to $\alpha_5\beta_1$ integrins, in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 3119-3119.	0.8	2
175	Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor D: Biology, Functions and Role in Cancer. , 2004, , 145-162.		0
176	The Current and Future Management of Malignant Ascites. <i>Clinical Oncology</i> , 2003, 15, 59-72.	0.6	128
177	Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. <i>British Journal of Cancer</i> , 2003, 89, 426-430.	2.9	85
178	A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. <i>British Journal of Cancer</i> , 2003, 89, 1152-1154.	2.9	35
179	Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. <i>British Journal of Radiology</i> , 2003, 76, S87-S91.	1.0	121
180	Carcinosarcoma of the ovary. <i>British Journal of Cancer</i> , 2003, 88, 654-657.	2.9	100

#	ARTICLE	IF	CITATIONS
181	Oral melphalan as a treatment for platinum-resistant ovarian cancer. <i>British Journal of Cancer</i> , 2003, 88, 1828-1830.	2.9	12
182	Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. <i>British Journal of Radiology</i> , 2003, 76, 153-162.	1.0	126
183	Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. <i>Biochemical Journal</i> , 2003, 375, 131-139.	1.7	39
184	Weekly platinum chemotherapy for recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2002, 86, 2-4.	2.9	7
185	Intra-tumoural microvessel density in human solid tumours. <i>British Journal of Cancer</i> , 2002, 86, 1566-1577.	2.9	262
186	ZD1839 (IRESSA [®]): a selective EGFR-TK inhibitor. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 161-168.	1.1	44
187	Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1484-1493.	3.0	266
188	The clinical development of the bryostatins. <i>Anti-Cancer Drugs</i> , 2002, 13, 673-683.	0.7	79
189	Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. <i>NMR in Biomedicine</i> , 2002, 15, 164-173.	1.6	81
190	VEGF antagonists. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 703-718.	1.4	39
191	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 465-469.	2.9	61
192	Heparan sulfate proteoglycans and cancer. <i>British Journal of Cancer</i> , 2001, 85, 1094-1098.	2.9	152
193	Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. <i>British Journal of Haematology</i> , 2000, 110, 292-299.	1.2	184
194	Requirement for expert histopathological assessment of ovarian cancer and borderline tumours. <i>British Journal of Cancer</i> , 2000, 82, 760-762.	2.9	18
195	Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 717-721.	1.2	12
196	Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. <i>Annals of Oncology</i> , 2000, 11, 201-206.	0.6	22
197	p53 And related proteins in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2000, 36, 2317-2328.	1.3	34
198	An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. <i>British Journal of Cancer</i> , 1999, 80, 444-447.	2.9	18

#	ARTICLE	IF	CITATIONS
199	Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. , 1999, 82, 298-304.		42
200	A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. British Journal of Cancer, 1998, 78, 366-369.	2.9	35
201	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. British Journal of Cancer, 1998, 78, 774-776.	2.9	35
202	Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 1998, 78, 1404-1406.	2.9	57
203	High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. Biomedical Applications, 1998, 709, 113-117.	1.7	7
204	Heparan Sulfate Undergoes Specific Structural Changes during the Progression from Human Colon Adenoma to Carcinoma in Vitro. Journal of Biological Chemistry, 1998, 273, 51-57.	1.6	119
205	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. European Journal of Cancer, 1997, 33, 2183-2193.	1.3	54
206	Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes. European Journal of Cancer, 1997, 33, 2171-2182.	1.3	11
207	Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. British Journal of Cancer, 1997, 75, 9-16.	2.9	94
208	Carcinomatous meningitis in solid tumours. Annals of Oncology, 1996, 7, 773-786.	0.6	93
209	A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. British Journal of Cancer, 1995, 72, 461-468.	2.9	113
210	Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunology, Immunotherapy, 1994, 39, 223-230.	2.0	43
211	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer, 1994, 74, 3135-3141.	2.0	113
212	Basic fibroblast growth factor increases the multiplication and migration of a serum-free derivative of CACO-2 but does not affect differentiation. Cancer Research, 1994, 54, 5718-23.	0.4	11
213	CALCIUM AND CANCER. Lancet, The, 1962, 280, 1328-1329.	6.3	1